IBDEI16R ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20163,1,4,0)
 ;;=4^C90.30
 ;;^UTILITY(U,$J,358.3,20163,2)
 ;;=^5001759
 ;;^UTILITY(U,$J,358.3,20164,0)
 ;;=D56.3^^84^929^184
 ;;^UTILITY(U,$J,358.3,20164,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20164,1,3,0)
 ;;=3^Thalassemia Minor
 ;;^UTILITY(U,$J,358.3,20164,1,4,0)
 ;;=4^D56.3
 ;;^UTILITY(U,$J,358.3,20164,2)
 ;;=^340497
 ;;^UTILITY(U,$J,358.3,20165,0)
 ;;=D56.9^^84^929^185
 ;;^UTILITY(U,$J,358.3,20165,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20165,1,3,0)
 ;;=3^Thalassemia,Unspec
 ;;^UTILITY(U,$J,358.3,20165,1,4,0)
 ;;=4^D56.9
 ;;^UTILITY(U,$J,358.3,20165,2)
 ;;=^340606
 ;;^UTILITY(U,$J,358.3,20166,0)
 ;;=M31.1^^84^929^187
 ;;^UTILITY(U,$J,358.3,20166,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20166,1,3,0)
 ;;=3^Thrombotic Microangiopathy
 ;;^UTILITY(U,$J,358.3,20166,1,4,0)
 ;;=4^M31.1
 ;;^UTILITY(U,$J,358.3,20166,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,20167,0)
 ;;=D51.2^^84^929^188
 ;;^UTILITY(U,$J,358.3,20167,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20167,1,3,0)
 ;;=3^Transcobalamin II Deficiency
 ;;^UTILITY(U,$J,358.3,20167,1,4,0)
 ;;=4^D51.2
 ;;^UTILITY(U,$J,358.3,20167,2)
 ;;=^5002286
 ;;^UTILITY(U,$J,358.3,20168,0)
 ;;=D05.92^^84^929^35
 ;;^UTILITY(U,$J,358.3,20168,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20168,1,3,0)
 ;;=3^Carcinoma in Situ Left Breast,Unspec Type
 ;;^UTILITY(U,$J,358.3,20168,1,4,0)
 ;;=4^D05.92
 ;;^UTILITY(U,$J,358.3,20168,2)
 ;;=^5001937
 ;;^UTILITY(U,$J,358.3,20169,0)
 ;;=D05.91^^84^929^37
 ;;^UTILITY(U,$J,358.3,20169,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20169,1,3,0)
 ;;=3^Carcinoma in Situ Right Breast,Unspec Type
 ;;^UTILITY(U,$J,358.3,20169,1,4,0)
 ;;=4^D05.91
 ;;^UTILITY(U,$J,358.3,20169,2)
 ;;=^5001936
 ;;^UTILITY(U,$J,358.3,20170,0)
 ;;=D05.90^^84^929^33
 ;;^UTILITY(U,$J,358.3,20170,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20170,1,3,0)
 ;;=3^Carcinoma in Situ Breast Unspec,Unspec Type
 ;;^UTILITY(U,$J,358.3,20170,1,4,0)
 ;;=4^D05.90
 ;;^UTILITY(U,$J,358.3,20170,2)
 ;;=^5001935
 ;;^UTILITY(U,$J,358.3,20171,0)
 ;;=D51.0^^84^929^189
 ;;^UTILITY(U,$J,358.3,20171,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20171,1,3,0)
 ;;=3^Vitamin B12 Deficiency Anemia d/t Intrinsic Factor Deficiency
 ;;^UTILITY(U,$J,358.3,20171,1,4,0)
 ;;=4^D51.0
 ;;^UTILITY(U,$J,358.3,20171,2)
 ;;=^5002284
 ;;^UTILITY(U,$J,358.3,20172,0)
 ;;=D51.1^^84^929^190
 ;;^UTILITY(U,$J,358.3,20172,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20172,1,3,0)
 ;;=3^Vitamin B12 Deficiency Anemia d/t Selective Vit B12 Malabsorp w/ Proteinuria
 ;;^UTILITY(U,$J,358.3,20172,1,4,0)
 ;;=4^D51.1
 ;;^UTILITY(U,$J,358.3,20172,2)
 ;;=^5002285
 ;;^UTILITY(U,$J,358.3,20173,0)
 ;;=D51.9^^84^929^192
 ;;^UTILITY(U,$J,358.3,20173,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20173,1,3,0)
 ;;=3^Vitamin B12 Deficiency Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,20173,1,4,0)
 ;;=4^D51.9
 ;;^UTILITY(U,$J,358.3,20173,2)
 ;;=^5002289
 ;;^UTILITY(U,$J,358.3,20174,0)
 ;;=D68.0^^84^929^194
 ;;^UTILITY(U,$J,358.3,20174,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20174,1,3,0)
 ;;=3^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,20174,1,4,0)
 ;;=4^D68.0
 ;;^UTILITY(U,$J,358.3,20174,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,20175,0)
 ;;=C88.0^^84^929^195
 ;;^UTILITY(U,$J,358.3,20175,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20175,1,3,0)
 ;;=3^Waldenstrom Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,20175,1,4,0)
 ;;=4^C88.0
 ;;^UTILITY(U,$J,358.3,20175,2)
 ;;=^5001748
 ;;^UTILITY(U,$J,358.3,20176,0)
 ;;=C91.02^^84^929^3
 ;;^UTILITY(U,$J,358.3,20176,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,20176,1,3,0)
 ;;=3^Acute Lymphoblastic Leukemia,In Relapse
